Matches in DBpedia 2014 for { <http://dbpedia.org/resource/LCZ696> ?p ?o. }
Showing items 1 to 31 of
31
with 100 items per page.
- LCZ696 abstract "LCZ696 is an investigational combination drug consisting of two antihypertensives (blood pressure lowering drugs), valsartan and AHU-377, in a 1:1 mixture. It is being developed by Novartis. The combination is often described as a dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) although the two effects are achieved by two different molecules.In Phase II clinical trials, LCZ696 was superior to valsartan alone in treating hypertension, and well tolerated. As of January 2012, a Phase III study for the same indication is under way. Additionally, the drug combination is being tested for the treatment of chronic heart failure. In April of 2014, this trial was stopped early due to a highly statistically significant reduction in cardiovascular mortality in the treatment arm. It is not clear whether LCZ696 is superior to the combination of valsartan with hydrochlorothiazide which has been marketed since the 1990s.".
- LCZ696 atcPrefix "none".
- LCZ696 pubchem "24755604".
- LCZ696 thumbnail Valsartan.svg?width=300.
- LCZ696 wikiPageID "34506987".
- LCZ696 wikiPageRevisionID "602573685".
- LCZ696 alt "AHU-377".
- LCZ696 alt "Valsartan".
- LCZ696 atcPrefix "none".
- LCZ696 class Angiotensin_II_receptor_antagonist.
- LCZ696 class "Neprilysin inhibitor".
- LCZ696 component "AHU-377".
- LCZ696 component "Valsartan".
- LCZ696 hasPhotoCollection LCZ696.
- LCZ696 image "AHU-377 skeletal.svg".
- LCZ696 legalStatus "Investigational".
- LCZ696 pubchem "24755604".
- LCZ696 routesOfAdministration "Oral".
- LCZ696 type "combo".
- LCZ696 subject Category:Antihypertensive_agents.
- LCZ696 subject Category:Combination_drugs.
- LCZ696 type Drug.
- LCZ696 type FunctionalSubstance.
- LCZ696 comment "LCZ696 is an investigational combination drug consisting of two antihypertensives (blood pressure lowering drugs), valsartan and AHU-377, in a 1:1 mixture. It is being developed by Novartis. The combination is often described as a dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) although the two effects are achieved by two different molecules.In Phase II clinical trials, LCZ696 was superior to valsartan alone in treating hypertension, and well tolerated.".
- LCZ696 label "LCZ696".
- LCZ696 sameAs m.0j26948.
- LCZ696 sameAs Q6457467.
- LCZ696 sameAs Q6457467.
- LCZ696 wasDerivedFrom LCZ696?oldid=602573685.
- LCZ696 depiction Valsartan.svg.
- LCZ696 isPrimaryTopicOf LCZ696.